MedTrace Logo

Regorafenib in Relapsed Glioblastoma

NCT02926222 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2022-09-09

No results posted yet for this study

Summary

This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.

Conditions

Interventions

DRUG

Regorafenib

Regorafenib is formulated as tablets of 40mg for oral administration.

DRUG

Lomustine

Lomustine is formulated as tablets of 40mg for oral administration.

Sponsors & Collaborators

  • BAYER S.p.A. - Italia

    collaborator UNKNOWN

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Vittorina Zagonel, MD · Istituto Oncologico Veneto IRCCS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-07-31
Completion
2021-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02926222 on ClinicalTrials.gov